{"id":"W3170399786","doi":"10.1200/jco.2021.39.15_suppl.tps7572","title":"ESCALADE: A phase 3 study of acalabrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for patients ≤65y with untreated non-germinal center B-cell–like (non-GCB) diffuse large B-cell lymphoma (DLBCL).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"Spinal Cord Injury BC","funders":"","keywords":"Medicine; Internal medicine; Population; Diffuse large B-cell lymphoma; CHOP; Gastroenterology; Rituximab; Vincristine; Phases of clinical research; Ibrutinib; Oncology; Cyclophosphamide; Surgery; Lymphoma; Chronic lymphocytic leukemia; Clinical trial; Leukemia; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00211906,0.0003852999,0.002578835,0.0003229566,0.00008516926,0.0000260201,0.0002575085,0.0004852854,0.00003784205],"category_scores_gemma":[0.001512296,0.000267359,0.0002377911,0.0005920924,0.0003567316,0.0002006848,0.0001869964,0.0008467597,0.000004067817],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002368015,"about_ca_system_score_gemma":0.01067124,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001774178,"about_ca_topic_score_gemma":0.0002877149,"domain_scores_codex":[0.9940553,0.000517795,0.003068662,0.0006179981,0.001052762,0.0006874678],"domain_scores_gemma":[0.992193,0.002697545,0.002000579,0.000450603,0.002021395,0.0006368094],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"nonrandomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1014334,0.5114452,0.3550447,0.0007304237,0.0006393187,0.005343009,0.001185702,0.00000784595,0.0003911733,0.000005536277,0.001791442,0.02198226],"study_design_scores_gemma":[0.7612563,0.09420729,0.1353433,0.0004780024,0.0007027748,0.000488765,0.0009962438,0.003417664,0.0007988009,0.00001460111,0.002059723,0.0002365146],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9966711,0.0002011939,0.000266123,0.000359164,0.0002913208,0.001724638,0.00004416946,0.00001037723,0.0004318764],"genre_scores_gemma":[0.9962956,0.000315631,0.002192859,0.0004133477,0.0001770248,0.00004792936,0.00005648627,0.00006567967,0.0004354698],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6598229,"threshold_uncertainty_score":0.9999779,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02757369438118631,"score_gpt":0.3926581560045246,"score_spread":0.3650844616233383,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}